Draft guideline on quality aspects of mRNA vaccines for veterinary use
Submitted by Anonymous (not verified) on 20 February 2026 - 12:00
Draft guideline on quality aspects of mRNA vaccines for veterinary use
Draft guideline on quality aspects of mRNA vaccines for veterinary use
Submitted by Anonymous (not verified) on 20 February 2026 - 12:00
Draft guideline on quality aspects of mRNA vaccines for veterinary use
PSUSA/00001307/202507
Submitted by Anonymous (not verified) on 20 February 2026 - 10:50
PSUSA/00001307/202507
Human medicines European public assessment report (EPAR): Palonosetron Accord, palonosetron, Date of authorisation: 26/05/2016, Revision: 10, Status: Authorised
Submitted by Anonymous (not verified) on 20 February 2026 - 10:10
Human medicines European public assessment report (EPAR): Palonosetron Accord, palonosetron, Date of authorisation: 26/05/2016, Revision: 10, Status: Authorised
Human medicines European public assessment report (EPAR): Lyvdelzi (previously Seladelpar Gilead), seladelpar lysine dihydrate, Revision: 4, Status: Authorised
Submitted by Anonymous (not verified) on 20 February 2026 - 9:40
Human medicines European public assessment report (EPAR): Lyvdelzi (previously Seladelpar Gilead), seladelpar lysine dihydrate, Revision: 4, Status: Authorised
Human medicines European public assessment report (EPAR): Kevzara, sarilumab, Date of authorisation: 23/06/2017, Revision: 16, Status: Authorised
Submitted by Anonymous (not verified) on 20 February 2026 - 9:34
Human medicines European public assessment report (EPAR): Kevzara, sarilumab, Date of authorisation: 23/06/2017, Revision: 16, Status: Authorised
Risk management requirements for elemental impurities in veterinary medicinal products - Scientific guideline
Submitted by Anonymous (not verified) on 20 February 2026 - 8:26
Risk management requirements for elemental impurities in veterinary medicinal products - Scientific guideline
Human medicines European public assessment report (EPAR): Klisyri, tirbanibulin, Date of authorisation: 16/07/2021, Revision: 6, Status: Authorised
Submitted by Anonymous (not verified) on 19 February 2026 - 15:00
Human medicines European public assessment report (EPAR): Klisyri, tirbanibulin, Date of authorisation: 16/07/2021, Revision: 6, Status: Authorised
Human medicines European public assessment report (EPAR): Uptravi, selexipag, Date of authorisation: 12/05/2016, Revision: 20, Status: Authorised
Submitted by Anonymous (not verified) on 19 February 2026 - 13:20
Human medicines European public assessment report (EPAR): Uptravi, selexipag, Date of authorisation: 12/05/2016, Revision: 20, Status: Authorised
Human medicines European public assessment report (EPAR): Enrylaze, crisantaspase, Date of authorisation: 15/09/2023, Revision: 1, Status: Authorised
Submitted by Anonymous (not verified) on 19 February 2026 - 12:40
Human medicines European public assessment report (EPAR): Enrylaze, crisantaspase, Date of authorisation: 15/09/2023, Revision: 1, Status: Authorised